Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Raise Hemoglobin

Trial Data Connects SGLT2 Inhibitors to Higher Red Blood Cell Counts

Sodium-glucose cotransporter 2 (SGLT2) inhibitors consistently increase hemoglobin and hematocrit concentrations in patients treated for cardiometabolic conditions.

The findings come from a systematic review and meta-analysis led by internist-nephrologist Dr. Michele Eisenga at University Medical Center Groningen, published in the Journal of the American Medical Association (JAMA).

Researchers evaluated 85 randomized clinical trials comprising 70,543 participants. These participants were receiving treatment for type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease. People with heart failure and chronic kidney disease often experience anemia, which lowers oxygen delivery across tissues. While earlier trials noted changes in blood values, the exact scale and biological drivers remained undetermined.

Modest Increases in Hemoglobin and Hematocrit Across 85 Trials

Patients receiving an SGLT2 inhibitor experienced higher red blood cell markers compared to those receiving placebos or alternative glucose-lowering drugs.

After a median follow-up period of 24 weeks, hemoglobin levels rose by an average of 0.60 g/dL. Hematocrit levels increased by an average of 2.36% relative to control groups.

These changes occurred reliably across diverse clinical study populations. The observed upward shifts were uniform, even though the absolute numerical gains remained modest. The authors noted that this consistency clarifies the typical hematologic response patients experience during standard therapy courses.

Shifts in Iron Stores and Erythropoietin Production

The meta-analysis revealed distinct alterations in how the body mobilizes iron stores while generating new red blood cells.

Patients assigned to SGLT2 inhibitors had higher concentrations of erythropoietin (EPO), the kidney-derived hormone responsible for stimulating bone marrow red blood cell production.

Along with elevated EPO, circulating ferritin and transferrin saturation levels dropped during active treatment. In contrast, total serum iron concentrations remained essentially stable. This pattern indicates that tissues draw upon existing internal iron reserves to fuel accelerated red blood cell synthesis.

Uncertain Clinical Impact on Long-Term Health Outcomes

The functional medical relevance of these laboratory shifts remains unconfirmed by researchers.

Current evidence does not establish whether modest gains in hemoglobin explain the known kidney and heart benefits associated with this drug class.

The observed changes provide mechanistic clues regarding cellular metabolism rather than proof of therapeutic protection. Further prospective trials must determine whether modifying red blood cell volume alters clinical event rates. Patients managing metabolic or renal conditions should talk to their clinician before making any adjustments to prescribed drug regimens.